Wall Street Zen upgraded shares of Black Diamond Therapeutics (NASDAQ:BDTX – Free Report) from a sell rating to a hold rating in a report issued on Saturday morning,Wall Street Zen reports.
BDTX has been the topic of several other research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Black Diamond Therapeutics in a research note on Friday, October 9th. Raymond James Financial reaffirmed an “outperform” rating on shares of Black Diamond Therapeutics in a research note on Thursday, August 6th. Jefferies Financial Group reiterated a “buy” rating on shares of Black Diamond Therapeutics in a report on Thursday, August 6th. Finally, TD Cowen reiterated a “buy” rating on shares of Black Diamond Therapeutics in a report on Thursday, August 6th. Seven analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $11.00.
Read Our Latest Analysis on Black Diamond Therapeutics
Black Diamond Therapeutics Stock Performance
Shares of Black Diamond Therapeutics stock opened at $1.69 on Friday. The stock’s 50-day moving average is $1.97 and its 200-day moving average is $2.21. Black Diamond Therapeutics has a one year low of $1.60 and a one year high of $4.94.
Black Diamond Therapeutics (NASDAQ:BDTX – Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($0.17) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.03. Equities research analysts expect that Black Diamond Therapeutics will post -0.57 EPS for the current year.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently modified their holdings of the company. BlackRock Inc. bought a new stake in shares of Black Diamond Therapeutics in the 2nd quarter valued at about $7,247,000. Connor Clark & Lunn Investment Management Ltd. bought a new position in Black Diamond Therapeutics during the second quarter worth about $2,022,000. AWM Investment Company Inc. bought a new position in Black Diamond Therapeutics during the second quarter worth about $1,850,000. Renaissance Technologies LLC grew its holdings in Black Diamond Therapeutics by 73.1% during the first quarter. Renaissance Technologies LLC now owns 1,643,747 shares of the company’s stock worth $3,501,000 after purchasing an additional 694,012 shares during the period. Finally, Dimensional Fund Advisors LP grew its holdings in Black Diamond Therapeutics by 51.9% during the first quarter. Dimensional Fund Advisors LP now owns 1,301,664 shares of the company’s stock worth $2,772,000 after purchasing an additional 444,649 shares during the period. Institutional investors own 95.47% of the company’s stock.
About Black Diamond Therapeutics
Black Diamond Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing precision medicines for genetically defined cancers. The company uses its proprietary MasterKey platform to identify and develop small-molecule therapies designed to address oncogenic mutations across multiple tumor types, including alterations that may be difficult to target with conventional approaches.
Black Diamond’s pipeline has included brain-penetrant therapies for cancers affecting the central nervous system.
Further Reading
- Five stocks we like better than Black Diamond Therapeutics
- Comfort Systems Earnings: AI Slowdown or More Growth Ahead?
- Bristol Myers Squibb’s Cancer Breakthrough Could Have Implications Beyond Its Own Stock
- 5 Beaten-Down Growth Stocks Trading Like Value Plays as Cash Chases Mega-Caps
- Anthropic’s IPO Filing Reveals a Massive Opportunity for AI Infrastructure Giants
Receive News & Ratings for Black Diamond Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Black Diamond Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
